Cong Xiao1, Shaoyun Zhang1, Nengji Long1, Wei Yu1, Yishan Jiang2. 1. Department of Orthopedics, The Third Hospital of Mianyang (Sichuan Mental Health Center), No. 190 The East Jiannan Road, Mianyang, 621000, China. 2. Department of Orthopedics, The Third Hospital of Mianyang (Sichuan Mental Health Center), No. 190 The East Jiannan Road, Mianyang, 621000, China. jiangysh@126.com.
Abstract
INTRODUCTION: The efficacy and safety of intravenous (IV) tranexamic acid (TXA) during hip fracture surgery remain controversial. This meta-analysis aimed to assess the efficacy of IV-TXA administration during hip fracture surgery for reducing the transfusion requirement and blood loss as well as its safety regarding the risk of thrombolysis. MATERIALS AND METHODS: PubMed, EMBASE, Web of Science, and the Cochrane Library Database were systematically searched for randomized controlled trials (RCTs) that focused on the efficacy and safety of IV-TXA in patients during hip fracture surgery. The primary outcome was the transfusion requirement. Secondary outcomes included total blood loss (TBL), deep vein thrombosis (DVT), and total thromboembolic events (TTEs). Risk ratio (RR), risk difference (RD), and mean difference (MD) for dichotomous and continuous data outcomes were determined from the meta-analysis. Data were analyzed using Rev Man 5.3. RESULTS: Altogether, 11 RCTs were included (total sample size 892 patients). IV-TXA significantly reduced the transfusion requirement [RR 0.60, 95% confidence interval (CI) 0.38-0.93, P = 0.02] and TBL (MD 326.64 ml, 95% CI - 462.23 to - 191.06, P < 0.00001) vs. cosntrol group. IV-TXA caused no increased risk of DVT (RD 0.02, 95% CI - 0.01 to 0.04, P = 0.13) or TTEs (RD 0.02, 95% CI - 0.01 to 0.05, P = 0.12). CONCLUSION: Available evidence indicates that IV-TXA efficaciously reduces TBL and transfusion requirements during hip fracture surgery without significantly increasing the risk of TTEs including DVT.
INTRODUCTION: The efficacy and safety of intravenous (IV) tranexamic acid (TXA) during hip fracture surgery remain controversial. This meta-analysis aimed to assess the efficacy of IV-TXA administration during hip fracture surgery for reducing the transfusion requirement and blood loss as well as its safety regarding the risk of thrombolysis. MATERIALS AND METHODS: PubMed, EMBASE, Web of Science, and the Cochrane Library Database were systematically searched for randomized controlled trials (RCTs) that focused on the efficacy and safety of IV-TXA in patients during hip fracture surgery. The primary outcome was the transfusion requirement. Secondary outcomes included total blood loss (TBL), deep vein thrombosis (DVT), and total thromboembolic events (TTEs). Risk ratio (RR), risk difference (RD), and mean difference (MD) for dichotomous and continuous data outcomes were determined from the meta-analysis. Data were analyzed using Rev Man 5.3. RESULTS: Altogether, 11 RCTs were included (total sample size 892 patients). IV-TXA significantly reduced the transfusion requirement [RR 0.60, 95% confidence interval (CI) 0.38-0.93, P = 0.02] and TBL (MD 326.64 ml, 95% CI - 462.23 to - 191.06, P < 0.00001) vs. cosntrol group. IV-TXA caused no increased risk of DVT (RD 0.02, 95% CI - 0.01 to 0.04, P = 0.13) or TTEs (RD 0.02, 95% CI - 0.01 to 0.05, P = 0.12). CONCLUSION: Available evidence indicates that IV-TXA efficaciously reduces TBL and transfusion requirements during hip fracture surgery without significantly increasing the risk of TTEs including DVT.
Entities:
Keywords:
Hip fracture; Meta-analysis; Thromboembolism; Tranexamic acid; Transfusion
Authors: Shahid Miangul; Timothy Oluwaremi; Joe El Haddad; Maamoun Adra; Nathan Pinnawala; Hayato Nakanishi; Reem H Matar; Christian A Than; Thomas M Stewart Journal: Eur J Orthop Surg Traumatol Date: 2022-09-26
Authors: Tobias Kammerer; Philipp Groene; Sophia R Sappel; Sven Peterss; Paula A Sa; Thomas Saller; Andreas Giebl; Patrick Scheiermann; Christian Hagl; Simon Thomas Schäfer Journal: Transfus Med Hemother Date: 2020-11-09 Impact factor: 3.747
Authors: Suk Yong Jang; Yong Han Cha; Jun Il Yoo; Taeho Oh; Jung Taek Kim; Chan Ho Park; Won Sik Choy; Yong Chan Ha; Kyung Hoi Koo Journal: J Korean Med Sci Date: 2020-09-21 Impact factor: 2.153
Authors: Francisco José Tarazona-Santabalbina; Cristina Ojeda-Thies; Jesús Figueroa Rodríguez; Concepción Cassinello-Ogea; José Ramón Caeiro Journal: Int J Environ Res Public Health Date: 2021-03-16 Impact factor: 3.390